Solid economic numbers in the global regions, higher yields, U.S. option expiration action and technical momentum continued to stimulate further asset allocation shifts into global equities. With the IPOX Alternative Beta strategies losing some relative momentum, a number of U.S. IPOs are lined up.
· Global equities continued to rally for a third week, supported by another week of big strength in emerging and China-linked markets. While U.S. earnings have been mixed thus far, focus was on the Nasdaq-100 (NDX: +2.31%) which finally managed to break through the key 2400 level to settle at 10-year highs with upward momentum tented on GOOG's (-6.24%) rare earnings miss towards the week-end.
· After last week's outperformance, most IPOX Strategy Portfolios traded in line with the benchmarks with the IPOX Global 50 (IPGL50) rising by another +2.94% to +5.89% YTD, underperforming benchmark MSCI World (MXWD) by just 14 bps. on the week. Performance within the IPOX Regional Strategy universe confirmed the global picture: In the United States, the IPOX U.S. universe (ETF: FPX) rose +1.84% to +5.62% YTD, lagging the S&P 500 (SPX) by 19 bps. In Europe, the IPOX Europe 50 (IPXUJPEU) rose +1.79% to +6.10%, a 34 bps. underperformance vs. benchmak Stoxx 50 (SX5P), while the IPOX Asia-Pacific 30 (IPTA) rose +3.77% to +5.37%, outperforming the MSCI Asia-Pacific by 42 bps. Upside focus within the IPOX Emerging Markets universe remained on the IPOX Latin America (IPXULATT: +6.10% to 12.64%). The IPOX Korea 30 (IPXK30K) lagged anew.
Recently listed large IPOs and spin-offs were amongst the best performers with the key Hong Kong Financials New China Life (1336 HK: +13.55%) and CITIC Securities (6030 HK: +17.32%), fashion IPOs Prada SpA (1913 HK: +13.13%) and Michael Kors (KORS UN: +10.50%) and U.S. listed Marathon Petroleum (MCP UN: +12.53%) and NXP Semiconductor (NXPI UN: +19.70%) leading the way
Alternative Beta - Key IPOX Strategy Returns YTD:
|YTD 2012 (%)||Name|
|IPGLC (NYSEARCA:USD)||3.32||6.72||IPOX Global Comp|
|IPGL100 (USD)||2.98||5.12||IPOX Global 100|
|IPGL50 (USD)||2.94||5.89||IPOX Global 50|
|IPGL30 (USD)||3.09||4.75||IPOX Global 30|
|IPXO (USD)||1.84||5.62||IPOX U.S. 100|
|IPXT (USD)||1.77||4.21||IPOX U.S. 30|
|IXTE (EUR)||1.53||5.41||IPOX Europe 30|
|IPXUJPEU (EUR)||1.77||6.10||IPOX Europe 50|
|IPTA (USD)||3.77||5.37||IPOX Asia-Pac. 30|
|IPXUEM (USD)||3.93||9.63||IPOX Emerging Mkts.|
|IPXUBRIC (USD)||5.50||9.70||IPOX BRIC 25|
|IPXUCHCP (USD)||4.32||9.09||Chin IPOX Comp.|
|CNI (USD)||5.22||6.96||China IPOX 20|
|IPXUCAUP (USD)||3.32||4.04||China IPOX Comp.|
|IPXULATT (USD)||6.86||12.64||IPOX LatAm 20|
|IPXK30K (KRW)||0.87||-0.08||IPOX Korea 30|
· Most significant IPOs launched (week 01/16/2012):
|Company||Ticker||Return / IPO (%)|
|Dong-A PharmTech Co Ltd||140410 KS||23.96%|
|Megalogic Technology Holdings||8242 HK||10.00%|
|Allied Cement Holdings Ltd||1312 HK||7.00%|
|Renewable Energy Group Inc||REGI US||-2.70%|
|Vision Fame International||1315 HK||55.83%|
|ASR Holdings Ltd||1803 HK||34.41%|
10 global IPOs launched last week with the average (median) IPO rising +11.80% (+8.50%). Initial sentiment in the micro/small-cap Hong Kong IPOs surged anew with the strongest gains amongst technology/service providers. The good debut of drug-maker Dong-A Pharmtech (140410 KS: +23.96%), which focuses on products related to prostatic hyperplasia and erectile dysfunction, underlines the strong momentum in the Korean IPO market.
· Week Ahead (01/23/2012): U.S. deal flow
|Guidewire Softw.||GWRE US||U.S.A.||CITI, DB|
|IntelePeer Inc||PEER US||U.S.A.||BCLY, DB|
|Verastem Inc||VSTM US||U.S.A.||UBS, Leerink|
With most Asian markets partially closed due to the Chinese New Year, IPOs in the U.S. will dominate the global IPO deal calendar. Amid growing risk appetite in all, the most notable deal is the USD 100m IPO of Guidewire Software (GWRE US), a software maker focusing on the property and casualty insurance industry. The profitable company sells a 15.78% stake, envisioning a market cap between USD 475-570m. At 2.71-3.25 times 2011 Revenues, we consider this a strong buy-and-hold. Fundamentally, the IPO of telecom service provider IntelePeer (PEER US) is less attractive: Amid a declining growth rate (Full 2011 numbers not updated in the SEC filing!!!), the P/E-backed company has yet to turn a profit. It is expected to sell 21.80%, equal to an initial market cap between USD 308-375m and around 3 times 2011 revenues. Biopharma/Cancer researcher Verastem (VSTM US) rounds up the U.S. deal calendar: The company without revenue sells 23.40% at an (envisioned) initial market cap between USD 173-211m. Based on our experience with the risk/return profile of recent biotech IPOs, we expect the initial price range to decrease significantly ahead of the IPO.
|Global||Josef Schuster||+ 1 312 268 1293|
|Mary Lee||+ 1 312 268 1294|
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.